GENova Biotherapeutics and Bridge Bioresearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced it has signed a collaboration agreement with Bridge Bioresearch Plc. ("Bridge Bioresearch"), an international drug development and discovery company that focuses on metabolic disorders.

The two biotechnology drug acquisition companies plan to leverage each others' scientific findings and industry contacts for mutual gain.

GENova's business solely focuses on cancer cures, while Bridge BioResearch is geared at acquiring drug targets for Obesity and Type 2 Diabetes. Through the collaboration agreement, the two companies will partner to share research results and their global contacts with research organizations and pharmaceutical companies. They will also examine their findings to gain insight into the links between their respective fields of oncology and obesity, as cancer and obesity are both maladies that can be blamed on lifestyle choices.

"By collaborating with Bridge BioResearch, we will gain access to their excellent network of high quality research labs and universities around the world, as well as their well-established distribution channels," says Aaron Whiteman, CEO for GENova. "We are confident that through this collaboration, we will gain access to the latest and greatest in developmental cancer drugs to perpetuate our acquisition pipeline, as well as secure reliable distribution channels for our out-licensing objectives."

"Furthermore, through this collaboration, we will exchange our scientific findings to gain insight into the links between obesity and cancer, as many findings suggest that one of the main factors in cancer development is lifestyle choices, including unhealthy diet," says Whiteman.